« Back
Home /
Givosiran

Givosiran

Item no.	HY-132610-10mg
Manufacturer	MedChem Express
CASRN	1639325-43-1
Amount	10 mg
Quantity options	10 mg 1 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	98.51
Citations	[1]Scott LJ. Givosiran: First Approval. Drugs. 2020 Feb;80(3):335-339.\|[2]Balwani M, et, al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med. 2020 Jun 11;382(24):2289-2301.
Smiles	[Givosiran]
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	ALN-AS1
Shipping Condition	Cool pack
Available
Manufacturer - Type	Oligonucleotides
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Small Interfering RNA (siRNA)
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, sealed storage, away from moisture)
Molecular Weight	16300.6 (1mg=61nmol; 5mg=307nmol)
Product Description	Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels. Givosiran can be used for the research of acute intermittent porphyria[1][2].
Manufacturer - Research Area	Neurological Disease
Solubility	10 mM in H2O
Manufacturer - Pathway	Epigenetics
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-132610-10mg-safety-datasheet.pdf